MedTrace Logo

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

NCT02319616 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2019-08-09

No results posted yet for this study

Summary

The primary objectives of this study are to investigate the efficacy and safety of topical steroid ointment (clobetasol 0.05%) for the treatment of the cutaneous manifestations of toxic epidermal necrolysis (TEN).

Conditions

  • Toxic Epidermal Necrolysis

Interventions

DRUG

Clobetasol 0.05% ointment

Blinded, daily application to one arm for a period of fourteen (14) days

DRUG

Placebo

Blinded, daily application to one arm for a period of fourteen (14) days

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Emanual Maverakis, MD · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-02-06
Completion
2019-02-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02319616 on ClinicalTrials.gov